BioMedomics Celebrates Sickle Cell Awareness Month

September is National Sickle Cell Awareness Month. Sickle cell disease is an inherited disease that distorts soft and round red blood cells and turns them into hard, crescent shaped cells. These distorted red blood cells can cause those affected to experience extreme pain and often requires numerous blood transfusions to increase the number of normal red blood cells in the body and unblock blood vessels. According to the American Red Cross, a patient with sickle cell disease may need up to 100 units of blood each year to treat complications from the disease.

BioMedomics would like to reaffirm our commitment to improving the quality of life and health outcomes of those affected by sickle cell disease. We encourage everyone to be part of this international effort to increase awareness about sickle cell disease and sickle cell trait. Individuals and organizations can join our efforts by donating blood, engaging elected officials for proclamations, and distributing educational information to dispel the myths about sickle cell disease.

BioMedomics™ Sickle SCAN® is a multiplexed, qualitative, point-of-care immunoassay to aid in the rapid diagnosis of sickle cell disorders. The test is made up of three indicators which detect the presence of hemoglobin A, S, and C, allowing the user to rapidly distinguish between normal, carrier, and sickle cell disease samples.

  • No electricity or instrumentation required
  • Combined sensitivity and specificity of >99%
  • Results in 5 minutes
  • Suitable for newborn screening
  • Ships worldwide

For more information, please email info@biomedomics.com. To place an order, please email sales@biomedomics.com.

Sickle SCAN® Approved by Department of Health in Australia!

We are excited to announce that the Therapeutic Goods Administration, a branch of the Department of Health in the Australian Government, has given BioMedomics, Inc. authorization to sell and distribute our world-renown Sickle SCAN® rapid test in Australia! We have partnered with Helena Laboratories Australia Pty Ltd to assist with distributing our product to customers.

Sickle SCAN® is the world’s leading Sickle Cell Disease detection test, winning over competitor testing methods with:

  • Fastest test result of 5 minutes
  • Highest sensitivity/specificity (99%/99%)
  • Differentiates trait from disease
  • NO specialized training required
  • NO electricity required

For information or questions about Sickle SCAN®, please email info@biomedomics.com

To receive a quote and place an order, please email sales@biomedomics.com

Sickle SCAN® Approved by the Tanzania Medicines and Medical Devices Authority!

We are excited to announce that the Tanzania Medicines and Medical Devices Authority has given authorization to BioMedomics, Inc. to sell and distribute our world-renown Sickle SCAN® rapid test in Tanzania! We have partnered with Laborex Tanzania Limited to assist with distributing our product to customers.

Sickle SCAN® is the world’s leading Sickle Cell Disease detection test, winning over competitor testing methods with:

  • Fastest test result of 5 minutes
  • Highest sensitivity/specificity (99%/99%)
  • Differentiates trait from disease
  • NO specialized training required
  • NO electricity required

For information or questions about Sickle SCAN®, please email info@biomedomics.com

To receive a quote and place an order, please email sales@biomedomics.com

BioMedomics™ Participates in Free Sickle Cell Screening Events Using Sickle SCAN® Rapid Test During MEA Rugby Championship

Morrisville, NC, USA – BioMedomics, a leader in innovative clinical diagnostics products that address global healthcare needs, participated in several sickle cell screening events in Nigeria during the recent Middle East-Africa Rugby League Championship tournament. The company used its Sickle SCAN Rapid Test during the events to screen people for sickle cell disease and sickle cell trait at no charge.

“What a great event to help raise awareness of sickle cell in Nigeria,” said BioMedomics CEO Frank Wang. “And the Sickle SCAN test was ideal for these kind of events because it provides results so quickly and reliably. The more people can know their status, the better.”

BioMedomics’ distribution partner in Nigeria, Assene-Laborex, helped organize and sponsor the events, which were held from October 2 to October 5. Euracare, a leading healthcare provider in Nigeria, provided clinical experts to conduct the tests, and the Nigeria Rugby League Association (NRLA) was the event host.

In addition to a location outside the tournament venue, Teslim Balogun Stadium, screening events were also held at a Lagos Euracare Clinic, Toyibat Comprehensive High School, and the University of Lagos. Ade Adebisi, Vice Chairman and General Manager of NRLA and Sickle SCAN spokesperson, was on hand for some of the events to meet and sign autographs for event participants. Adebisi is a former professional rugby player who has sickle cell disease and works as an advocate for awareness, diagnosis, and treatment for the disease.

Clinical SS_2019 Alvarez_Pediatrics

Sickle SCAN Clinical Study, Alvarez OA, Hustace T, Voltaire M, et al. Newborn Screening for Sickle Cell Disease Using Point-of-Care Testing in Low-Income Setting. Pediatrics. 144(4):e20184105; 2019